Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.
2.

Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.

National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group.

Ann Emerg Med. 2005 Sep;46(3):243-52.

PMID:
16126134
3.

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.

Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T.

N Engl J Med. 1999 Jun 10;340(23):1781-7.

5.
6.

Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Hertzberg V, Ingall T, O'Fallon W, Asplund K, Goldfrank L, Louis T, Christianson T.

Clin Trials. 2008;5(4):308-15. doi: 10.1177/1740774508094404.

PMID:
18697845
7.

Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ.

Stroke. 2004 Oct;35(10):2418-24. Epub 2004 Sep 2.

9.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

10.

The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.

Kwiatkowski T, Libman R, Tilley BC, Lewandowski C, Grotta JC, Lyden P, Levine SR, Brott T; National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.

Ann Emerg Med. 2005 Apr;45(4):377-84.

PMID:
15795715
11.
12.

Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.

Feng W, Vasquez G, Suri MF, Lakshminarayan K, Qureshi AI.

J Stroke Cerebrovasc Dis. 2011 May-Jun;20(3):241-6. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.003. Epub 2010 Jul 10.

PMID:
20621509
13.
15.

Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials.

Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M.

Stroke. 2007 Dec;38(12):3205-12. Epub 2007 Nov 1.

16.

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.

Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M.

Stroke. 2000 Oct;31(10):2335-41.

17.

Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.

Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, Meier D.

Stroke. 1998 Oct;29(10):2073-5.

18.

Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.

Grotta JC, Welch KM, Fagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD.

Stroke. 2001 Mar;32(3):661-8.

19.

Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.

Weir CJ, Kaste M, Lees KR; Glycine Antagonist in Neuroprotection (GAIN) International Steering Committee and Investigators.

Stroke. 2004 Sep;35(9):2111-6. Epub 2004 Jul 8.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk